CORD-19:0376103fd7863b10e41a0f59fe226be9765f34c7 / 21137-21476 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T106","span":{"begin":0,"end":339},"obj":"Sentence"},{"id":"TextSentencer_T106","span":{"begin":0,"end":339},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"68 As outlined in Table 2 benefits of MSC therapy in experimental adult lung diseases include, but are not limited to, improvements in alveolar, airway, and vascular structure; attenuation of lung inflammation; decreased pulmonary fibrosis; reduced pulmonary edema, hemorrhage, and alveolar and endothelial permeability; and Abbreviations:"}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T106","span":{"begin":0,"end":339},"obj":"Sentence"}],"text":"68 As outlined in Table 2 benefits of MSC therapy in experimental adult lung diseases include, but are not limited to, improvements in alveolar, airway, and vascular structure; attenuation of lung inflammation; decreased pulmonary fibrosis; reduced pulmonary edema, hemorrhage, and alveolar and endothelial permeability; and Abbreviations:"}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T93","span":{"begin":72,"end":85},"obj":"Disease"},{"id":"T94","span":{"begin":197,"end":209},"obj":"Disease"},{"id":"T95","span":{"begin":221,"end":239},"obj":"Disease"},{"id":"T96","span":{"begin":249,"end":264},"obj":"Disease"}],"attributes":[{"id":"A93","pred":"mondo_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A94","pred":"mondo_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0002771"},{"id":"A96","pred":"mondo_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/MONDO_0006932"}],"text":"68 As outlined in Table 2 benefits of MSC therapy in experimental adult lung diseases include, but are not limited to, improvements in alveolar, airway, and vascular structure; attenuation of lung inflammation; decreased pulmonary fibrosis; reduced pulmonary edema, hemorrhage, and alveolar and endothelial permeability; and Abbreviations:"}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T31","span":{"begin":72,"end":85},"obj":"Phenotype"},{"id":"T32","span":{"begin":221,"end":239},"obj":"Phenotype"},{"id":"T33","span":{"begin":249,"end":264},"obj":"Phenotype"}],"attributes":[{"id":"A31","pred":"hp_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/HP_0002088"},{"id":"A32","pred":"hp_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/HP_0002206"},{"id":"A33","pred":"hp_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/HP_0100598"}],"text":"68 As outlined in Table 2 benefits of MSC therapy in experimental adult lung diseases include, but are not limited to, improvements in alveolar, airway, and vascular structure; attenuation of lung inflammation; decreased pulmonary fibrosis; reduced pulmonary edema, hemorrhage, and alveolar and endothelial permeability; and Abbreviations:"}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T132","span":{"begin":72,"end":76},"obj":"Body_part"},{"id":"T133","span":{"begin":192,"end":196},"obj":"Body_part"}],"attributes":[{"id":"A132","pred":"uberon_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A133","pred":"uberon_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"68 As outlined in Table 2 benefits of MSC therapy in experimental adult lung diseases include, but are not limited to, improvements in alveolar, airway, and vascular structure; attenuation of lung inflammation; decreased pulmonary fibrosis; reduced pulmonary edema, hemorrhage, and alveolar and endothelial permeability; and Abbreviations:"}